Format

Send to

Choose Destination
See comment in PubMed Commons below
Kidney Int. 2017 Aug 28. pii: S0085-2538(17)30477-5. doi: 10.1016/j.kint.2017.06.017. [Epub ahead of print]

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.

Author information

1
Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: david.cherney@uhn.on.ca.
2
Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
3
Helsinki University Hospital, University of Helsinki and Minerva Institute for Medical Research, Helsinki, Finland.
4
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
5
Boehringer Ingelheim Norway KS, Asker, Norway.

Abstract

Sodium glucose cotransporter 2 (SGLT2) inhibitors reduce HbA1c, blood pressure, and weight in patients with type 2 diabetes. To investigate the effect of renal function on reductions in these parameters with the SGLT2 inhibitor empagliflozin, we assessed subgroups by baseline estimated glomerular filtration rate (eGFR; Modification of Diet in Renal Disease) in pooled data from five 24-week trials of 2286 patients with type 2 diabetes randomized to empagliflozin or placebo. Reductions in HbA1c with empagliflozin versus placebo significantly diminished with decreasing baseline eGFR. Reductions in systolic blood pressure (SBP) with empagliflozin were maintained in patients with lower eGFR. The mean placebo-corrected changes from baseline in systolic blood pressure at week 24 with empagliflozin were -3.2 (95% confidence interval -4.9,-1.5) mmHg, -4.0 (-5.4, -2.6) mmHg, -5.5 (-7.6, -3.4) mmHg, and -6.6 (-11.4, -1.8) mmHg in patients with an eGFR of 90 or more, 60 to 89, 30 to 59, and under 30 ml/min/1.73m2, respectively. Similar trends were observed for diastolic blood pressure. Weight loss with empagliflozin versus placebo tended to be attenuated in patients with a lower eGFR. Results were consistent in a 12-week ambulatory blood pressure monitoring trial in 823 patients with type 2 diabetes and hypertension. Thus, unlike HbA1c reductions, systolic blood pressure and weight reductions with empagliflozin are generally preserved in patients with chronic kidney disease.

KEYWORDS:

SGLT2 inhibition; diabetic nephropathy; glomerular filtration rate; kidney diseases

PMID:
28860019
DOI:
10.1016/j.kint.2017.06.017
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center